How will the new EU Health Technology Assessment (HTA) Regulation impact drug and medical device evaluations across Europe? This article from the Danish Medicines Agency provides a clear overview of the regulation, its objectives, and what it means for reimbursement decisions and market access. As the EU moves towards a more harmonized approach to HTA, increasing the speed of developing high quality evidence is crucial for stakeholders in healthcare and pharmaceuticals, and this is why the first use case of the EVA project is centered around this topic.
Article:
https://laegemiddelstyrelsen.dk/en/reimbursement/the-eu-hta-regulation/
